Long-term complete remission of large hepatocellular adenoma after bariatric surgery

Dantas, Anna Carolina Batista; Filho, Marco A. Santo; Jeismann, Vagner Birk; Faria, Luisa Leitão de; Muniz, Renan Rosetti; Rocha, Manoel de Souza; Herman, Paulo; Santo, Marco Aurélio

doi:10.1016/j.orcp.2021.03.008

Cited by 2 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the representative risk factors for HCA are oral contraceptives and anabolic steroids, obesity and metabolic syndrome are also known risk factors for HCA and are especially associated with IHCA and shHCA [19,[92][93][94][95]. HCA in obese patients often regresses after weight loss, especially after bariatric surgery, which may prevent the need for liver resection [96][97][98][99]. This confirms the importance of obesity in the development of HCA and suggests that weight loss may become the first therapeutic option for HCA in obese patients.…”

Section: Mechanisms Of Hcc Development In Masldmentioning

confidence: 65%

Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors

Takahashi,

Dungubat,

Kusano

et al. 2023

Biomedicines

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is characterized by excessive fat accumulation in the livers of patients without a history of alcohol abuse. It is classified as either simple steatosis (nonalcoholic fatty liver) or nonalcoholic steatohepatitis (NASH), which can progress to liver cirrhosis and hepatocellular carcinoma (HCC). Recently, it was suggested that the terms “metabolic dysfunction-associated steatotic liver disease (MASLD)” and “metabolic dysfunction-associated steatohepatitis (MASH)” should replace the terms “nonalcoholic fatty liver disease (NAFLD)” and “nonalcoholic steatohepatitis (NASH)”, respectively, with small changes in the definitions. MASLD, a hepatic manifestation of metabolic syndrome, is rapidly increasing in incidence globally, and is becoming an increasingly important cause of HCC. Steatohepatitic HCC, a histological variant of HCC, is characterized by its morphological features resembling non-neoplastic steatohepatitis and is closely associated with underlying steatohepatitis and metabolic syndrome. Variations in genes including patatin-like phospholipase domain-containing protein 3 (PNPLA3), transmembrane 6 superfamily 2 (TM6SF2), and membrane-bound O-acyltransferase domain-containing protein 7 (MBOAT7) are associated with the natural history of MASLD, including HCC development. The mechanisms of HCC development in MASLD have not been fully elucidated; however, various factors, including lipotoxicity, inflammation, reactive oxygen species, insulin resistance, and alterations in the gut bacterial flora, are important in the pathogenesis of MASLD-associated HCC. Obesity and MASLD are also recognized as risk factors for hepatocellular adenomas, and recent meta-analyses have shown an association between MASLD and intrahepatic cholangiocarcinoma. In this review, we outline the pathology and pathogenesis of MASLD-associated liver tumors.

show abstract

Section: Mechanisms Of Hcc Development In Masldmentioning

confidence: 65%

Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors

Takahashi,

Dungubat,

Kusano

et al. 2023

Biomedicines

View full text Add to dashboard Cite

show abstract

“…Anabolic steroid use is another hormonal risk factor for the development of HCAs 16–19 . Obesity, metabolic syndrome, 20–26 vascular liver diseases (VLDs), 27–31 genetic diseases 32–43 and alcohol consumption 7 have also been identified as predisposing factors. Table 1 summarises the main risk factors, including several liver diseases associated with HCAs 44,45 .…”

Section: Risk Factorsmentioning

confidence: 99%

“…Overweight/obesity, which is often associated with diabetes type 2 and NASH, particularly in the USA and Europe, favour the emergence of HCA, namely IHCA, b‐IHCA, and shHCA (Table 1). 20–26,70,71,97,98 It is of note that obesity as such may increase the risk of HCC in the non‐cirrhotic liver 99 …”

Section: Hca In Particular Clinicopathological Contextsmentioning

confidence: 99%

“…Overweight/obesity, which is often associated with diabetes type 2 and NASH, particularly in the USA and Europe, favour the emergence of HCA, namely IHCA, b-IHCA, and shHCA (Table 1). [20][21][22][23][24][25][26]70,71,97,98 It is of note that obesity as such may increase the risk of HCC in the non-cirrhotic liver. 99 GSD is well known to be associated with various kinds of benign nodules (FNH, FNH-like, macroregenerative nodules, and different HCA subtypes, except for H-HCA), as well as a high risk of malignant nodules.…”

Section: Hca In Particular Clinicopathological Contexts M E T a B O L...mentioning

confidence: 99%

See 1 more Smart Citation

Hepatocellular adenoma: what we know, what we do not know, and why it matters

et al. 2022

View full text Add to dashboard Cite

Hepatocellular adenoma: what we know, what we do not know, and why it mattersIn the last two decades there has been significant progress in research on and diagnosis of hepatocellular adenoma (HCA), resulting in the establishment of a molecular and immunohistological HCA classification. This review aims to fine-tune the current expertise in order to enhance the histopathological diagnostic possibilities, by refining issues that are already known, addressing diagnostic difficulties, and identifying still unknown aspects of HCA. We discuss novel methods to identify HCA subtypes, in particular the sonic hedgehog HCAs and the interpretation of glutamine synthetase patterns for the recognition of b-cateninmutated HCAs. The major complications of HCAs, i.e. bleeding and malignant transformation, are considered, including the dilemmas of atypical and borderline lesions. HCAs in different clinical and geographical settings, e.g. pregnancy, cirrhosis and non-western countries, are also discussed. The natural history of the different HCA subtypes in relation to age, sex and risk factors is a feature that is still insufficiently investigated. This is also true for the risks of clinical bleeding and malignant transformation in association with HCA subtypes. As HCA is a relatively rare tumour, a multicentre and multidisciplinary approach across geographical boundaries will be the appropriate method to establish prospective programmes with which to identify, classify and manage HCAs, focusing on several aspects, e.g. aetiology, underlying liver disease, complications, regression, and growth. Updating what we know and identifying and addressing what we do not know matters for optimal patient management.

show abstract

Long-term complete remission of large hepatocellular adenoma after bariatric surgery

Cited by 2 publications

References 8 publications

Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors

Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors

Hepatocellular adenoma: what we know, what we do not know, and why it matters

Contact Info

Product

Resources

About